Cancer of Oesophagus or Gastricus – New Assessment of Technology of Endosonography (COGNATE): report of pragmatic randomised trial

IT Russell,1,2* RT Edwards,3 AE Gliddon,1 DK Ingledew,4 D Russell,1,2 R Whitaker,1 ST Yeo,3 SE Attwood,5 H Barr,6 S Nanthakumaran7 and KGM Park7

1North Wales Organisation for Randomised Trials in Health (NWORTH), Bangor University, Bangor, UK
2College of Medicine, Swansea University, Swansea, UK
3Centre for Economics and Policy in Health, Bangor University, Bangor, UK
4School of Psychology, Bangor University, Bangor, UK
5North Tyneside General Hospital, North Shields, UK
6Gloucestershire Royal Hospital, Gloucester, UK
7Aberdeen Royal Infirmary, Aberdeen, UK

*Corresponding author

Scientific summary

Cancer of Oesophagus or Gastricus – New Assessment of Technology of Endosonography

Health Technology Assessment 2013; Vol. 17: No. 39
DOI: 10.3310/hta17390

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Each year in the UK, 13,000 patients are diagnosed with gastro-oesophageal cancer. It is the fourth most common cause of cancer death. The general prognosis of patients with gastro-oesophageal cancer is poor: fewer than 10% survive 5 years. However there have been many advances in the treatment of these tumours, so it is important to select the most appropriate management plan for each patient. Endoscopic ultrasonography, introduced in the early 1980s, became common practice in the early 2000s. Mounting an ultrasonic probe on an endoscope can improve staging, and guide management, of gastro-oesophageal tumours. Endoscopic ultrasound (EUS) itself is safe and does not impose greater risks on patients than endoscopy.

However there has been no published or current randomised trial to evaluate whether EUS is effective and cost-effective in the management of gastro-oesophageal cancer. So the National Institute of Health Research Health Technology Assessment (NIHR HTA) programme commissioned the COGNATE (Cancer of Oesophagus or Gastricus – New Assessment of Technology of Endosonography) team to evaluate this. Our philosophy was pragmatic in the sense that, after randomising patients to EUS or not, participating centres followed best practice in staging and managing gastro-oesophageal cancer, but without the constraints of a rigid clinical protocol.

Objectives

As the link between staging and managing gastro-oesophageal cancer was not clear, we did not know whether EUS improved management decisions. To monitor the long-term sequelae of EUS, we collected data on participants’ treatment plans, changes to them, subsequent progress and use of health care. Evidence that EUS improves choice of treatment and patient outcome would benefit individual patients and the population of patients with gastro-oesophageal cancer by targeting resources better.

Thus COGNATE evaluated, not the accuracy of EUS, but the effect it has on patient management and subsequent survival and quality of life. Most previous assessments of EUS staging neglected patients with non-surgical treatment but COGNATE adopted a broader approach because, if EUS leads to less surgery, it is as important to measure effects on patients who do not receive surgery as on patients who do. In short, COGNATE assessed whether the addition of EUS to usual staging tests changes treatment, improves survival and quality of life, and uses resources cost-effectively. The COGNATE team also developed a quality assurance process for EUS scans.

Methods

Design and interventions

COGNATE was a pragmatic, eight-centred, two-arm randomised controlled trial. All patients with gastro-oesophageal cancer received standard staging algorithms, after which the relevant multidisciplinary team (MDT) chose a provisional management plan from: endoscopic mucosal resection (EMR); immediate surgery; surgery after neo-adjuvant chemotherapy; and chemotherapy and radiotherapy. In principle patients randomised to the intervention group then received EUS, while those randomised to the control group continued with their agreed management plan.
Setting
The trial took place in eight British hospitals, two of which – Aberdeen Royal Infirmary, a teaching hospital, and Gloucestershire Royal Hospital, a district general hospital – contributed most participants.

Participants
Participants were eligible for the trial if they had cancer of the oesophagus, stomach or gastro-oesophageal junction and had not started treatment. To be randomised, patients had to be free of metastatic disease, fit for surgery (even if not planned) and graded less than 3 on both ASA (American Society of Anesthesiologists) and WHO (World Health Organization) criteria. Clinicians could exclude from the trial any patient for whom they were not in equipoise about the value of EUS. The trial co-ordinating centre monitored all exclusions and reasons given.

We invited eligible patients to participate in the trial, gave them the patient information sheet approved by the Multi-centre Research Ethics Committee for Scotland, and allowed them time to study it and ask questions. We stressed that the choice of treatment after EUS was the same in both groups. We then asked consenting patients to sign the approved consent form.

Randomisation
We stratified consented patients by centre and tumour location, and randomised them in equal proportions between EUS and not – by telephone call to the co-ordinating centre, which used dynamic software to prevent subversion.

Sample size
Our original application proposed survival as the primary outcome and a target of 700 patients. Difficulty in recruiting centres led us to change the primary outcome to ‘quality-adjusted survival’ and the target to a maximum of 400 and a minimum of 220. The latter would yield 80% power to detect a hazard ratio of 0.5, or a ‘small’ effect size of 0.4 in quality of life, or some combination of these.

Follow up
We followed participants until death or the end of data collection, which was between 12 and 54 months after recruitment. We collected data at discharge from hospital after initial treatment and at follow-up clinics after 1, 3, 6, 12, 18, 24 and 36 months.

Outcome measures
To compare the two randomised groups we used:

(a) quality-adjusted survival (primary outcome)
(b) survival censored at between 12 months (for those last recruited) and 54 months
(c) participant-reported quality of life using three questionnaires: European Quality of Life – 5 Dimensions (EQ-5D) (generic), Functional Assessment of Cancer Therapy – General (FACT-G) scale (cancer related) and FACT Additional Concerns (FACT-AC) scale (gastro-oesophageal cancer specific)
(d) process of care:
   ○ changes in management plans agreed by MDTs
   ○ complete resection rate, and
   ○ adverse events related to EUS
(e) use of health-care resources.

Psychometric methods to refine quality-of-life measurement
We asked participants to assess their quality of life through EQ-5D and FACT, specifically the general module (FACT-G), the oesophageal module [Functional Assessment of Cancer Therapy – Oesophageal (FACT-E)] and the gastric module [Functional Assessment of Cancer Therapy – Gastric (FACT-Ga)]. As FACT-E and FACT-Ga have many similar questions, the FACT team encouraged us to combine them into a single ‘Additional Concerns’ module. We used factor analysis to examine the structure of FACT and thereby
assess whether to aggregate these two modules into one. We used structural equation modelling to
examine the relationships between EQ-5D and FACT scores, and thereby assess whether EQ-5D reflected all
aspects of quality of life experienced by these patients.

**Statistical methods**
Primary analysis was by allocated group, whether or not participants received EUS. This reflects the
pragmatic nature of the trial and our aim of evaluating EUS in informing decisions in the real world.
We used baseline characteristics, including quality-of-life scores, as covariates to improve the precision
and generalisability of the model. Although blinding participants to their allocation was neither possible
nor desirable, those responsible for analysis remained blind until the Trial Steering Committee and Data
Monitoring and Ethics Committee had reviewed the definitive analysis.

**Economic methods**
We assessed the cost-effectiveness of EUS in the diagnosis and treatment of gastro-oesophageal cancer
by estimating differences between the cost of patients’ care including EUS, and the cost when limited to
conventional staging; and corresponding differences in effectiveness as estimated by quality-adjusted life-
years (QALYs). We used ‘bootstrapping’ to overcome the skewed data and cost-effectiveness acceptability
curves to quantify uncertainty.

In accordance with National Institute for Health and Care Excellence (NICE) guidance we analysed
COGNATE from the perspective of the NHS, focusing on health-care resources used by participants after
randomisation. These included investigation, treatment and palliation, and other elements of secondary
and pharmaceutical care. The local co-ordinator at each trial site used an electronic database to record the
use of NHS resources by participants throughout the period of the trial. To cost these resources, we refined
and used published national unit costs.

We used sensitivity analysis to explore whether or not the estimated benefits and costs of endoscopic
ultrasonic staging relative to conventional staging were sensitive to key features of our analysis, notably
the cost of EUS scans.

**Quality assurance of endoscopic ultrasound scans**
The COGNATE team asked trial sites to record EUS scans as videos and their interpretations on a
proforma. A panel of six COGNATE investigators reviewed 20 anonymised scans (21% of 97 performed
within COGNATE trial), both individually before, and together during, five web-based conferences. Each
conference reached a blinded consensus on the staging of four tumours. We compared the original report
with the staging decisions of individual reviewers, their consensus and that of an external reviewer.

**Results**
We randomised 223 patients, of whom 213 (96%) yielded enough data for primary analysis. Over three-
quarters of participants were male, and nearly half were over 65 years. The most common tumour site was
the oesophagus and the most common tumour type was adenocarcinoma. The most common tumour
stage was T3, and slightly more participants had nodal stage N1 than N0. At the end of the trial 44% of
EUS participants and 32% of control participants were alive.

Our psychometric analyses confirmed that it was appropriate to aggregate the FACT-E and FACT-Ga
modules into a single Additional Concerns module. The structural equation modelling suggested that
EQ-5D scores captured individuals’ physical and functional well-being but not their social and emotional
well-being as measured by FACT. There are two possible explanations for this: either EQ-5D items do not
cover these domains; or the general public in weighting the health states defined by EQ-5D chose to give
little weight to social and emotional issues. However EQ-5D utility scores correlated well with EQ-5D visual analogue scores. This is consistent with patients and the public agreeing that physical and functional well-being deserve more weight, possibly because of the extreme nature of gastro-oesophageal cancer. Thus our preparatory analysis supported our use of EQ-5D as a generic measure of quality of life, and persuaded us to adjust survival using not only EQ-5D, but also FACT-G and FACT-AC.

Endoscopic ultrasound significantly improved participant survival, with a hazard ratio of 0.706 [95% confidence interval (CI) from 0.501 to 0.996] and an increase of 121 days in estimated median survival – from 1.63 years in the control group to 1.96 years in the intervention group. Participants reported consistent, although non-significant, improvements in mean outcomes at 12 months, notably a difference of 0.061 (95% CI from –0.043 to 0.164) in mean EQ-5D scores between 0.449 in the control group and 0.509 in the intervention group; and a difference of 0.12 (95% CI from –0.27 to 0.51) in mean FACT-G between 2.15 in the control group and 2.27 in the intervention group. Combining survival and quality of life, EUS improved survival adjusted for generic quality of life with a hazard ratio of 0.705 (95% CI from 0.499 to 0.995) and an increase of 66 days in estimated median quality-adjusted survival – from 0.94 QALYs in the control group to 1.12 QALYs in the intervention group.

Trial sites reported consistent, although non-significant, reductions in total resource use in secondary and pharmaceutical care (including EUS scans when undertaken), generating mean savings of about £2860 (95% ‘bootstrapped’ CI from –£2200 to £8000) from an average of £32,000 with a standard deviation (SD) of £22,000 in the control group to £29,200 (SD £14,900) in the intervention group. Combining these estimated benefits and savings yields probability of 96.6% that EUS is cost-effective in the sense of achieving the NICE criterion of costing less than £20,000 to gain a QALY.

The benefits of EUS were significantly greater for those with poor initial quality of life, but did not differ between centres. Similarly there was a significant interaction between initial quality of life and the effect of EUS on all the FACT scales; again, sicker patients benefitted more from EUS. However there was no significant difference between intervention and control groups in mean FACT scores adjusted for covariates. There were no serious adverse reactions attributable to EUS.

Both management plans and final treatment varied between centres. EUS increased the proportion of tumours completely resected from 80% (44 out of 55) to 91% (48 out of 53). Furthermore participants allocated to EUS who then transferred to a ‘therapeutic’ treatment, namely EMR or surgery in some form, survived much better than control subjects who made this change, and better than intervention participants confirmed for one of these ‘therapeutic’ treatments. The few intervention participants who transferred to ‘conservative’ treatment, namely chemotherapy, radiotherapy or both, survived worse than both the control subjects who made this change and intervention participants confirmed for ‘conservative’ treatment. In contrast, control subjects who changed plans in either direction experienced intermediate survival, arguably because they lacked the discriminatory power of EUS. In short, changes are consistently more appropriate in the intervention group than in the control group. Although all of these analyses have low power, and are therefore not statistically significant, they underpin the significant differences in outcomes, and help to explain them.

The quality assurance panel achieved excellent agreement on the tumour node metastasis (TNM) staging of the 20 endoscopic ultrasonic films. Their web-based conferences failed to agree staging for only one T stage and only one N stage, and reached consensus agreeing with the original investigator on 19 T stages and 17 N stages. There was excellent agreement between the original investigator and the consensus on T stage (weighted kappa = 0.866; \( p < 0.001 \)) and moderate agreement on N stage (kappa = 0.562; \( p = 0.012 \)). In short, we developed an effective quality assurance process for EUS scans. It provides a useful model for future NIHR-funded assessments of diagnostic technologies and has the potential to improve routine clinical practice.
Conclusions

Although EUS was common practice by the time COGNATE began recruiting in 2005 we achieved the first rigorous evaluation of EUS. The COGNATE team ameliorated many problems of recruiting centres and participants, mainly through two centres – Aberdeen and Gloucester. EUS achieved a surprising combination of significant improvements in survival (121 days) and quality-adjusted survival (66 days); a substantial, although non-significant, net saving of £2800 per trial participant; and, combining these statistical and economic findings, 96.6% probability of being cost-effective by NICE criteria. We judge that these impressive findings provide strong evidence in favour of EUS scans for all patients with gastro-oesophageal cancer who have the potential to benefit.

As the COGNATE team ‘caught the EUS horse just as it was leaving the stable’, we make no recommendation for future research into EUS. Instead we recommend:

1. policy-orientated research into the best time to evaluate new technologies
2. methodological research to streamline the collection of data to evaluate complex technologies such as EUS, notably on the costs of the extensive care for conditions such as gastro-oesophageal cancer, and
3. psychometric research to refine the integrated Functional Assessment of Cancer Therapy – Oesophageal and Gastric (FACT-EG) module as a valid measure of the outcome of gastro-oesophageal cancer.

Trial registration

This trial is registered as ISRCTN1444215.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Publication

Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)

Five-year impact factor: 5.804

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 01/01/03. The contractual start date was in June 2003. The draft report began editorial review in June 2010 and was accepted for publication in November 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Russell et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Tom Marshall  Reader in Primary Care, School of Health and Population Sciences, University of Birmingham, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, NICE, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk